Intravenous clarithromycin: A valuable immunomodulator for severe infections
There are many studies suggesting that intake of a macrolide in the treatment regimen is linked with improved outcomes for patients with community-acquired pneumonia. However this was never proved through one randomized clinical study (RCT). We reviewed all pre-clinical and clinical development from...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Association of medical doctors Sanamed Novi Pazar
2014-01-01
|
| Series: | Sanamed |
| Subjects: | |
| Online Access: | http://sanamed.rs/sanamed_pdf/sanamed_9_1/Konstantinos_Leventogian.pdf |
| Summary: | There are many studies suggesting that intake of a macrolide in the treatment regimen is linked with improved outcomes for patients with community-acquired pneumonia. However this was never proved through one randomized clinical study (RCT). We reviewed all pre-clinical and clinical development from 2003 to 2014 for intravenous clarithromycin as adjunctive treatment of severe infections. This process ended with the conduct of two RCTs; the first in 200 patients with ventilator-associated pneumonia; and the second in 600 patients with proven or suspected Gram-negative infections of non-pulmonary origin. The two RCTs has similar findings; significant decrease of mortality of patients with septic shock and multiple organ dysfunctions; and shorter resolution of severe infections. The second RCT also showed significant savings for survivors. These data support the use of intravenous clarithromycin as adjunctive treatment of severe infections. |
|---|---|
| ISSN: | 1452-662X 2217-8171 |